TP53 and B-cell chronic lymphocytic leukemia: In chronic lymphocytic leukemia (CLL), identification of TP53 mutations, as well as of chromosome 17 deletions, that occur in about 5–10% of patients at diagnosis and more frequently at relapse, has a relevant clinical impact, making the chemo-immunotherapy not advisable for this kind of patients [81].